Advertisement

Rheumatology International

, Volume 39, Issue 3, pp 497–507 | Cite as

Incidence of infection other than tuberculosis in patients with autoimmune rheumatic diseases treated with bDMARDs: a real-time clinical experience from India

  • S. ChandrashekaraEmail author
  • Vineeta Shobha
  • Vijay Rao
  • Anu Desai
  • Ramesh Jois
  • B. G. Dharmanand
  • Sharath Kumar
  • Pradeep Kumar
  • Chethana Dharmapalaiah
  • Kurugodu Mathada Mahendranath
  • Shiva Prasad
  • Manisha Ashwin Daware
  • Yogesh Singh
  • Uma Karjigi
  • S. Nagaraj
  • K. R. Anupama
Observational Research
  • 44 Downloads

Abstract

Biologic disease-modifying anti-rheumatic drugs (bDMARD) have transformed the treatment paradigm of chronic autoimmune rheumatic diseases (ARDs), but they are often associated with adverse drug reactions. The present study evaluated the frequency, characteristics and type of infections, other than tuberculosis (TB), in ARD patients receiving bDMARDs. The multicentre, cross-sectional, retrospective, observational study was conducted across 12 centers in Karnataka, India, between January to August 2016. The study included patients receiving bDMARD therapy for various ARDs. Outcome variables considered were any infection, minor infections and major infections, other than TB. Clinical variables were compared between infection and no infection group, and the increase in the likelihood of infection with respect to various clinical variables was assessed. The study involved 209 subjects with a median (range) age of 41 (16–84) years and male to female ratio of 0.97:1. A total of 29 (13.88%) subjects developed infection following bDMARD therapy, out of whom a majority had minor infection (n = 26). The likelihood of developing any infection was noted to be more in subjects receiving anti-TNF (golimumab, P = 0.03) and those on three or more conventional synthetic (cs) DMARDs (P < 0.01). Infection risk was higher in patients with systemic lupus erythematosus (P = 0.04), other connective tissue disease (P < 0.01) and in patients with comorbidities (P = 0.13). The risk of infection was associated with the use of anti-TNF therapy and more than three csDMARDs, co morbidities and Adds such as systemic lupus erythematosus and connective tissue disease.

Keywords

bDMARDs Infection ARDs csDMARDS Comorbidities 

Notes

Acknowledgements

The authors acknowledge the help of Research Assist (http://www.research-assist.com) for editing and formatting the manuscript.

Funding

Karnataka Rheumatology Association (Association of rheumatologists).

Compliance with ethical standards

Conflict of interest

Authors S. Chandrashekara, Vineeta Shobha, Vijay Rao, Anu Desai, Ramesh Jois, B. G. Dharmanand, Sharath Kumar, Pradeep Kumar, Chethana Dharmapalaiah, Kurugodu Mathada Mahendranath, Shiva Prasad, Manisha Ashwin Daware, Yogesh Singh, Uma Karjigi, Nagaraj S, and K. R. Anupama declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

296_2019_4245_MOESM1_ESM.docx (30 kb)
Supplementary material 1 (DOCX 30 KB)

References

  1. 1.
    Yamanaka H, Goto K, Suzuki M (2012) Bacterial infection in the limbs of patients with rheumatoid arthritis during biological agent therapy. Open J Rheumatol Autoimmune Dis 2:47–52CrossRefGoogle Scholar
  2. 2.
    Hofmann K, Clauder A-K, Manz RA (2018) Targeting B cells and plasma cells in autoimmune diseases. Front Immunol 9:835CrossRefGoogle Scholar
  3. 3.
    Boyman O, Comte D, Spertini F (2014) Adverse reactions to biologic agents and their medical management. Nat Rev Rheumatol 10:612–627CrossRefGoogle Scholar
  4. 4.
    Pichler WJ (2006) Adverse side-effects to biological agents. Allergy 61:912–920CrossRefGoogle Scholar
  5. 5.
    Her M, Kavanaugh A (2016) Alterations in immune function with biologic therapies for autoimmune disease. J Allergy Clin Immunol 137:19–27CrossRefGoogle Scholar
  6. 6.
    Singh JA, Cameron C, Noorbaloochi S et al (2015) Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet 386:258–265CrossRefGoogle Scholar
  7. 7.
    Díaz-Lagares C, Pérez-Alvarez R, García-Hernández FJ et al (2011) Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label. Arthritis Res Ther 13:R112CrossRefGoogle Scholar
  8. 8.
    Aletaha D, Neogi T, Silman AJ et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580–1588CrossRefGoogle Scholar
  9. 9.
    Petri M, Orbai A-M, Alarcón GS et al (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677–2686CrossRefGoogle Scholar
  10. 10.
    Rudwaleit M, van der Heijde D, Landewé R et al (2011) The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70:25–31CrossRefGoogle Scholar
  11. 11.
    Taylor W, Gladman D, Helliwell P et al (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–2673CrossRefGoogle Scholar
  12. 12.
    Dougados M, van der Linden S, Juhlin R et al (1991) The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 34:1218–1227CrossRefGoogle Scholar
  13. 13.
    Chopra A (2012) Epidemiology of rheumatoid arthritis. In: Mukherjee S, Ghosh A (ed) Monograph on rheumatoid arthritis. Indian College of Physicians, Academic Wing of API India, Marksman Media Service, Kolkata, pp 1–9Google Scholar
  14. 14.
    Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE (2002) Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 46:2287–2293CrossRefGoogle Scholar
  15. 15.
    Singh JA (2016) Infections with biologics in rheumatoid arthritis and related conditions: a scoping review of serious or hospitalized infections in observational studies. Curr Rheumatol Rep 18:61CrossRefGoogle Scholar
  16. 16.
    Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DPM (2006) Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54:2368–2376CrossRefGoogle Scholar
  17. 17.
    Smitten AL, Choi HK, Hochberg MC et al (2008) The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 35:387–393Google Scholar
  18. 18.
    Quartuccio L, Zabotti A, Zotto SD, Zanier L, De Vita S, Valent F (2018) Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: use-fulness of administrative data. J Adv Res.  https://doi.org/10.1016/j.jare.2018.09.003 Google Scholar
  19. 19.
    Yun H, Xie F, Delzell E et al (2016) Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in medicare. Arthritis Rheumatol 68:56–66CrossRefGoogle Scholar
  20. 20.
    Wolfe F, Michaud K, Anderson J, Urbansky K (2004) Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 50:372–379CrossRefGoogle Scholar
  21. 21.
    Kalb RE, Fiorentino DF, Lebwohl MG et al (2015) Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatol 151:961–969CrossRefGoogle Scholar
  22. 22.
    Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Sève P (2014) Adult-onset Still’s disease. Autoimmun Rev 13:708–722CrossRefGoogle Scholar
  23. 23.
    Ruscitti P, Giacomelli R (2018) Pathogenesis of adult onset still’s disease: current understanding and new insights. Expert Rev Clin Immunol 14:965–976CrossRefGoogle Scholar
  24. 24.
    Maria AT, Le Quellec A, Jorgensen C, Touitou I, Rivière S, Guilpain P (2014) Adult onset Still’s disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions. Autoimmun Rev 13:1149–1159CrossRefGoogle Scholar
  25. 25.
    Peckham D, Scambler T, Savic S, McDermott MF (2017) The burgeoning field of innate immune-mediated disease and autoinflammation. J Pathol 241:123–139CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • S. Chandrashekara
    • 1
    Email author
  • Vineeta Shobha
    • 2
  • Vijay Rao
    • 3
  • Anu Desai
    • 2
  • Ramesh Jois
    • 4
  • B. G. Dharmanand
    • 5
  • Sharath Kumar
    • 6
  • Pradeep Kumar
    • 7
  • Chethana Dharmapalaiah
    • 8
  • Kurugodu Mathada Mahendranath
    • 9
  • Shiva Prasad
    • 10
  • Manisha Ashwin Daware
    • 11
  • Yogesh Singh
    • 3
  • Uma Karjigi
    • 7
  • S. Nagaraj
    • 12
  • K. R. Anupama
    • 1
  1. 1.ChanRe Rheumatology and Immunology Center and ResearchBangalore-10India
  2. 2.St. John’s Medical College HospitalBangaloreIndia
  3. 3.Manipal HospitalBangaloreIndia
  4. 4.Fortis HospitalBangaloreIndia
  5. 5.SAKRA HospitalBangaloreIndia
  6. 6.Columbia Asia HospitalBangaloreIndia
  7. 7.Apollo HospitalBangaloreIndia
  8. 8.Aster CMI HospitalBangaloreIndia
  9. 9.Samarpan Health CentreBangaloreIndia
  10. 10.Vikram Hospital and Heart CareMysoreIndia
  11. 11.Narayana Health CityBangaloreIndia
  12. 12.SPARSH HospitalBangaloreIndia

Personalised recommendations